(Reuters) - Ranbaxy Laboratories Ltd (RANB.NS) has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering ...
Generic Diovan is coming. The Wall Street Journal reports that generics drugmaker Ranbaxy has scored an FDA approval to manufacture an off-brand version of the blood pressure medication. The drug will ...
Although the patent on valsartan (Diovan, Novartis) expired last Friday, a generic version of the popular antihypertensive drug has yet to make it to market. By contrast, a generic version of Diovan ...
A few years ago India’s Alkem Laboratories was in the hot seat with the FDA, having had several plants cited by inspectors. Today it is in the driver’s seat after the agency approved its new generic ...
Ranbaxy’s export woes may be hurting its own sales, but the Indian generics firm is actually making life easier for Novartis. Ranbaxy currently holds exclusive rights to sell the generic version of ...
Novartis took its first big hit from new Diovan generics during last year's third quarter, when Ranbaxy Laboratories finally won approval for its exclusive generic of the blood pressure pill. And it ...
EAST HANOVER, N.J., Aug. 4 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge ...
EAST HANOVER, N.J., Dec. 3 /PRNewswire/ -- Diovan(R) (valsartan), an angiotensin receptor blocker or ARB, has been approved following a priority review by the U.S. Food and Drug Administration (FDA) ...
Credit: Getty Images. The approval was based on data from 3 clinical studies that assessed the antihypertensive effect of valsartan in 290 children 1 to less than 6 years of age. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback